Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on precision targeted alpha therapies (TAT) for cancer treatment. Its lead candidate, VMT-a-NET, is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors who have not previously received peptide-targeted radiopharmaceutical therapy like Lutathera. The company also has VMT01, in Phase 1/2a trials for second-line or later treatment of MC1R-positive metastatic melanoma, and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. Additionally, it develops Pluvicto, a beta-emitting radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer. Perspective Therapeutics collaborates with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab for melanoma.

Perspective Therapeutics, Inc. is listed on the NYSE American exchange under the ticker symbol CATX. The company trades in United States Dollars (USD). As a US-based company, its stock is traded in the US market, providing liquidity for investors interested in the radiopharmaceutical sector.

Perspective Therapeutics operates in the Healthcare sector, specifically within the Medical Devices industry. However, its primary focus is on radiopharmaceutical development, which involves creating targeted alpha therapies for cancer treatment. The company's work bridges medical devices and pharmaceuticals, as it develops both therapeutic agents and imaging-related technologies for oncology.

Perspective Therapeutics is headquartered in Seattle, Washington, United States. The company primarily serves the US market, as indicated by its focus on clinical trials and regulatory pathways within the country. Its operations are centered on developing and commercializing radiopharmaceuticals for cancer patients in the United States.

Perspective Therapeutics operates as a development-stage radiopharmaceutical company, generating value through its pipeline of targeted alpha therapies. Its key assets include VMT-a-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting fibroblast activation protein. The company also has Pluvicto, a beta-emitting therapy for prostate cancer. It collaborates with Bristol Myers Squibb to test VMT01 with nivolumab. Perspective Therapeutics does not yet have approved products, so it currently does not generate revenue from product sales; its business model relies on advancing clinical trials and potential future partnerships or licensing deals.